NUREXONE BIOLOGIC INC. (F:J90) — Market Cap & Net Worth
Market Cap & Net Worth: NUREXONE BIOLOGIC INC. (J90)
NUREXONE BIOLOGIC INC. (F:J90) has a market capitalization of $40.29 Million (€34.46 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #22655 globally and #1994 in its home market, demonstrating a -1.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NUREXONE BIOLOGIC INC.'s stock price €0.38 by its total outstanding shares 90681345 (90.68 Million).
NUREXONE BIOLOGIC INC. Market Cap History: 2017 to 2026
NUREXONE BIOLOGIC INC.'s market capitalization history from 2017 to 2026. Data shows growth from $3.82 Million to $40.29 Million (32.10% CAGR).
NUREXONE BIOLOGIC INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NUREXONE BIOLOGIC INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of J90 by Market Capitalization
Companies near NUREXONE BIOLOGIC INC. in the global market cap rankings as of May 5, 2026.
Key companies related to NUREXONE BIOLOGIC INC. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
NUREXONE BIOLOGIC INC. Historical Marketcap From 2017 to 2026
Between 2017 and today, NUREXONE BIOLOGIC INC.'s market cap moved from $3.82 Million to $ 40.29 Million, with a yearly change of 32.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €40.29 Million | -1.81% |
| 2025 | €41.03 Million | -9.15% |
| 2024 | €45.16 Million | +149.12% |
| 2023 | €18.13 Million | -22.97% |
| 2022 | €23.54 Million | +534.29% |
| 2019 | €3.71 Million | +2.94% |
| 2018 | €3.60 Million | -5.56% |
| 2017 | €3.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of NUREXONE BIOLOGIC INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.29 Million USD |
| MoneyControl | $40.29 Million USD |
| MarketWatch | $40.29 Million USD |
| marketcap.company | $40.29 Million USD |
| Reuters | $40.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more